Close Menu
    Facebook X (Twitter) Instagram
    Friday, November 20
    Top Stories:
    • FDA to Miss Savara Drug Decision Deadline After 3-Month Delay
    • New Study Redefines a Major Brain Speech Hub
    • Author Correction: Global Bispecific Antibody Patents and Therapies
    Facebook X (Twitter) Instagram Pinterest Vimeo
    IO Tribune
    • Home
    • AI
    • Tech
      • Gadgets
      • Fashion Tech
    • Crypto
    • Smart Cities
      • IOT
    • Science
      • Space
      • Quantum
    • OPED
    IO Tribune
    Home » FDA to Miss Savara Drug Decision Deadline After 3-Month Delay
    Science

    FDA to Miss Savara Drug Decision Deadline After 3-Month Delay

    Lina Johnson MercilliBy Lina Johnson MercilliNovember 20, 2026No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Fast Facts

    • FDA again delayed Savara’s Molbreevi decision, missing November 22 without setting a new deadline.
    • The inhaled drug could become the first approved treatment for autoimmune pulmonary alveolar proteinosis.
    • Stock fell 18% after announcement; analysts cite FDA capacity issues, not rejection.
    • Phase 3 data and analyst confidence support approval; peak sales could exceed $500 million.

    A rare-disease decision is delayed again

    The FDA will miss its Nov. 22 decision date for Savara’s inhaled drug candidate, molgramostim, which may be marketed as Molbreevi. The agency has not provided a new date.

    The decision was already delayed by three months in April. At that time, the FDA said Savara’s answers to its questions required a major amendment to the application. Savara said the earlier delay was not related to safety, effectiveness or manufacturing.

    Promise for patients, uncertainty for investors

    Molgramostim is being developed for autoimmune pulmonary alveolar proteinosis, or PAP, a rare lung disease that can cause serious complications, including lung scarring. If approved, it would be the first FDA-approved treatment for the condition.

    In a 48-week trial, the drug improved a measure of lung function compared with a placebo at 24 weeks, meeting the study’s main goal. Still, a delayed decision leaves patients and investors waiting. Savara shares fell 18% at Friday’s market open.

    More review time, but no new deadline

    Analysts at Jefferies and Guggenheim said they remain confident in the drug’s prospects, pointing to the trial results and Savara’s work to address manufacturing questions. However, the FDA has not explained why it needs more time. The delay alone does not confirm approval—or rejection.

    For people living with PAP, an approved inhaled treatment could offer a new option and improve daily life. Yet the next step is unclear. The FDA’s decision will determine whether the promising research becomes an available treatment.

    Continue Your Tech Journey

    Explore the future of technology with our detailed insights on Artificial Intelligence.

    Stay inspired by the latest discoveries from NASA.

    Sci-BioV1

    Asia Biotech health Innovation Medical medicine Tech VT1
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleAI’s Most Misunderstood Graph Gets a Major Update
    Avatar photo
    Lina Johnson Mercilli
    • Website

    Lina Johnson Marcelli is the editor for IO Tribune, bringing over two decades of experience in journalism to her role. With a BA in Journalism, she is passionate about delivering impactful stories that resonate with readers. Known for her keen editorial vision and leadership, Lina is dedicated to fostering innovative storytelling across the publication. Outside of work, she enjoys exploring new media trends and mentoring aspiring journalists.

    Related Posts

    AI

    AI’s Most Misunderstood Graph Gets a Major Update

    November 20, 2026
    Science

    What Happens When Male Bumblebees Stay in the Nest?

    November 20, 2026
    Gadgets

    WhatsApp Group Chats Now Support 1,500 Members

    November 20, 2026
    Add A Comment

    Comments are closed.

    Must Read

    FDA to Miss Savara Drug Decision Deadline After 3-Month Delay

    November 20, 2026

    AI’s Most Misunderstood Graph Gets a Major Update

    November 20, 2026

    What Happens When Male Bumblebees Stay in the Nest?

    November 20, 2026

    WhatsApp Group Chats Now Support 1,500 Members

    November 20, 2026

    Muse Unleashes Instagram Pettiness

    November 20, 2026
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    Most Popular

    Switching from Polars to Pandas: Worth It?

    August 12, 2026

    Navigating AI’s Next Frontier: Speedy Solutions and Savvy Insights Await! | MIT News

    November 6, 2025

    Morse Micro Launches High-Power Wi-Fi HaLow Module

    June 2, 2026
    Our Picks

    Unlock May’s Mystical Skies: Witness the Milky Way’s Core!

    May 8, 2026

    Could ETH Hit $20K by 2026? AI Analyzes Tom Lee’s Bold Prediction!

    December 7, 2025

    Snag the Bose QuietComfort Ultra: Now $150 Off!

    January 14, 2026
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    • Privacy Policy
    • Disclaimer
    • Terms and Conditions
    • About Us
    • Contact us
    Copyright © 2025 Iotribune.comAll Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.